GlassScriptPhysician profile
Zheng Chen
NPI 1669878807
$7,371.20
in general payments reported to CMS, 2019-2025
29 companies · $4,172 in 2025
The $4,172 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $213 · 2023: $805 · 2024: $1,705 · 2025: $4,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,682.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,390.62 | 2021-2025 | |
| Janssen Biotech, INC. | $1,086.01 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $759.22 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $613.72 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $515.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $497.77 | 2021-2025 | Livdelzi, Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.45 | 2023-2025 | Xifaxan |
| Ardelyx, INC. | $397.17 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $220.00 | 2021-2023 | |
| Intra-Sana Laboratories | $200.00 | 2022 | |
| Aimmune Therapeutics, INC. | $168.62 | 2024-2025 | Zenpep, Vowst |
| Celltrion USA INC. | $164.75 | 2024-2025 | Vegzelma |
| Genzyme Corporation | $109.80 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $103.32 | 2024 | Zeposia |
| Celgene Corporation | $101.12 | 2022-2024 | Zeposia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $91.61 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $85.13 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $71.16 | 2024-2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $68.66 | 2025 | Monoferric |
| Intercept Pharmaceuticals, INC. | $67.37 | 2025 | |
| Janssen Scientific Affairs, LLC | $63.77 | 2023-2024 | Stelara, Tremfya |
| Caris Mpi, INC. | $29.40 | 2025 | Mi Cancer Seek |
| Braintree Laboratories, INC. | $29.22 | 2021-2023 | Suflave, Sutab |
| Organon LLC | $27.84 | 2025 | Hadlima |
| Boston Scientific Corporation | $25.73 | 2024 | Wavewriter Alpha Prime 16 |
| Exact Sciences Corporation | $23.39 | 2025 | The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $16.69 | 2025 | Givlaari |
| Evoke Pharma, INC. | $15.43 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $15.30 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zheng Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.